Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 19/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16981646 | 0.81 | PDE9A (0.58) | PDE9A | |
| SCHEMBL3002324 | 0.79 | PDE9A (0.53) | PDE9A | |
| SCHEMBL889777 | 0.79 | ALDH1A1 (0.56) | — | |
| SCHEMBL17604242 | 0.78 | PDE9A (0.55) | PDE9A | |
| SCHEMBL7877139 | 0.77 | PNP (0.49) | — | |
| SCHEMBL22071806 | 0.76 | LMNA (0.59) | PDE9A | |
| SCHEMBL17604296 | 0.76 | PDE9A (0.53) | PDE9A | |
| SCHEMBL24097627 | 0.76 | PNP (0.48) | — | |
| SCHEMBL11618229 | 0.76 | ALDH1A1 (0.65) | PDE9A | |
| SCHEMBL21126169 | 0.75 | PNP (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2023-09-26 | — | — | US | disclosed |
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-09-14 | — | — | US | disclosed |
| US-20220152078-A1 | 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2022-05-19 | — | — | US | disclosed |
| US-20220143061-A1 | 3'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2022-05-12 | — | — | US | disclosed |
| US-11203610-B2 | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2021-12-21 | — | — | US | disclosed |
| US-11149052-B2 | 2′3′-cyclic dinucleotides | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2021-10-19 | — | — | US | disclosed |
| US-10966999-B2 | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2021-04-06 | — | — | US | disclosed |
| US-20210009630-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-14 | — | — | US | disclosed |
| US-20190322697-A1 | 2'2'-CYCLIC DINUCLEOTIDES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR,V.V.I. (CZ) | 2019-10-24 | — | — | US | disclosed |
| US-20190322695-A1 | 2'3'-CYCLIC DINUCLEOTIDES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR,V.V.I. (CZ) | 2019-10-24 | — | — | US | disclosed |
| US-20190185510-A1 | 2'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2019-06-20 | — | — | US | disclosed |
| US-20170002355-A1 | cGAP-PNA MULTIVALENT PEPTIDE NUCLEIC ACID LIGAND DISPLAY | THE USA, AS REPRESENTED BY THE SECRETARY, DEPART- MENT OF HEALTH AND HUMAN SERVICES (US) | 2017-01-05 | — | — | US | disclosed |
| US-20140148500-A1 | PROGRAMMABLE SELF-ASSEMBLED NANOSTRUCTURES BASED ON SIDECHAIN-MODIFIED PNA FOR THE MULTIVALENT DISPLAY OF LIGANDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322697-A1 | 2'2'-CYCLIC DINUCLEOTIDES | STING1, CGAS, MAVS | PDE9A 992/4885 |
| US-10966999-B2 | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein | STING1, IRF3, MAVS | PDE9A 516/4885 |
| US-11149052-B2 | 2′3′-cyclic dinucleotides | STING1, MAVS, CGAS | PDE9A 1191/4885 |
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | PDE9A 199/4885 |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | STING1, MAVS, CGAS | PDE9A 814/4885 |
| US-20170002355-A1 | cGAP-PNA MULTIVALENT PEPTIDE NUCLEIC ACID LIGAND DISPLAY | CGAS, STING1, IAPP | PDE9A 463/4885 |
| US-20220143061-A1 | 3'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | STING1, CGAS, IRF3 | PDE9A 26/4885 |
| US-20140148500-A1 | PROGRAMMABLE SELF-ASSEMBLED NANOSTRUCTURES BASED ON SIDECHAIN-MODIFIED PNA FOR THE MULTIVALENT DISPLAY OF LIGANDS | NCL, PARN, COIL | PDE9A 1636/4885 |
| US-20220152078-A1 | 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | STING1, CGAS, NT5C2 | PDE9A 44/4885 |
| US-20190322695-A1 | 2'3'-CYCLIC DINUCLEOTIDES | STING1, MAVS, CGAS | PDE9A 1182/4885 |
| US-11203610-B2 | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein | STING1, CGAS, IRF3 | PDE9A 568/4885 |
| US-20190185510-A1 | 2'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN | STING1, CGAS, IRF3 | PDE9A 602/4885 |
| US-20210009630-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | PDE9A 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.